Free Trial

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

-0.02 (-2.17%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
3.02 million shs
Average Volume
1.18 million shs
Market Capitalization
$158.41 million
P/E Ratio
Dividend Yield
Price Target

Rigel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
543.6% Upside
$5.81 Price Target
Short Interest
3.23% of Shares Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.07) to $0.04 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.27 out of 5 stars

Medical Sector

661st out of 915 stocks

Pharmaceutical Preparations Industry

295th out of 399 stocks

RIGL stock logo

About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

RIGL Stock Price History

RIGL Stock News Headlines

RIGL Apr 2024 3.000 call
Rigel Pharma Names Rojkjaer EVP, Chief Medical Officer
Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals: Q4 Earnings Insights
Rigel Pharmaceuticals Inc. Q4 Earnings Summary
See More Headlines
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$116.88 million
Book Value
($0.18) per share


Free Float
Market Cap
$158.41 million

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Raul R. Rodriguez (Age 63)
    President, CEO & Director
    Comp: $1.17M
  • Mr. Dean L. Schorno CPA (Age 61)
    Executive VP & CFO
    Comp: $736.72k
  • Mr. Raymond J. Furey J.D. (Age 56)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $683k
  • Mr. David A. Santos (Age 61)
    Executive VP & Chief Commercial Officer
    Comp: $737.18k
  • Ms. Julie Patel
    Senior VP of Human Resources
  • Dr. Esteban S. Masuda (Age 62)
    Executive Vice President of Research
    Comp: $537.21k
  • Mr. Joseph Lasaga (Age 49)
    Executive VP & Chief Business Officer
  • Dr. Lisa Rojkjaer M.D. (Age 58)
    Executive VP & Chief Medical Officer
  • Mr. Tarek Sallam
    Vice President of Marketing

RIGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Rigel Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RIGL shares.
View RIGL analyst ratings
or view top-rated stocks.

What is Rigel Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for Rigel Pharmaceuticals' shares. Their RIGL share price targets range from $1.25 to $15.00. On average, they predict the company's stock price to reach $5.81 in the next twelve months. This suggests a possible upside of 543.6% from the stock's current price.
View analysts price targets for RIGL
or view top-rated stocks among Wall Street analysts.

How have RIGL shares performed in 2024?

Rigel Pharmaceuticals' stock was trading at $1.45 on January 1st, 2024. Since then, RIGL shares have decreased by 37.7% and is now trading at $0.9031.
View the best growth stocks for 2024 here

When is Rigel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our RIGL earnings forecast

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. The biotechnology company earned $29.53 million during the quarter, compared to the consensus estimate of $31.28 million. During the same period in the previous year, the business earned ($0.08) earnings per share.

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Raul Rodriguez has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.34%), Acadian Asset Management LLC (3.12%), Jacobs Levy Equity Management Inc. (1.31%), CM Management LLC (1.14%), GSA Capital Partners LLP (0.79%) and Healthcare of Ontario Pension Plan Trust Fund (0.77%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez.
View institutional ownership trends

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RIGL) was last updated on 5/24/2024 by Staff

From Our Partners